Comparing adjuvanted H28 and modified vaccinia virus ankara expressingH28 in a mouse and a non-human primate tuberculosis model.
Here we report for the first time on the immunogenicity and protective efficacy of a vaccine strategy involving the adjuvanted fusion protein "H28" (consisting of Ag85B-TB10.4-Rv2660c) and Modified Vaccinia Virus Ankara expressing H28. We show that a heterologous prime-boost regimen involv...
Guardado en:
Autores principales: | Rolf Billeskov, Jan P Christensen, Claus Aagaard, Peter Andersen, Jes Dietrich |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1ca9f198111c4064be7677c0c7543eb3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination.
por: Tara Elvang, et al.
Publicado: (2009) -
The Efficacy of Disinfection on Modified Vaccinia Ankara and African Swine Fever Virus in Various Forest Soil Types
por: Franziska Tanneberger, et al.
Publicado: (2021) -
Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo
por: Arwen F. Altenburg, et al.
Publicado: (2017) -
Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome.
por: Julie Delaloye, et al.
Publicado: (2009) -
Retrospective Analysis of 28 Cases of Tuberculosis in Pregnant Women in China
por: Qiang Li, et al.
Publicado: (2019)